Cefine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefine

Quick Facts
Active ingredient Cefixime
Form Tablet, capsule, oral suspension, chewable tablet
Pharmacological class Third-generation cephalosporin antibiotic
General purpose Elimination of susceptible bacterial infections
Origin Semisynthetic

Cefine: What Type of Medicine is It?

Cefine is a prescription-only medication containing the active ingredient Cefixime, which is classified as a third-generation cephalosporin antibiotic. It functions as a broad-spectrum anti-infective, designed to combat a wide variety of susceptible bacterial infections. This advanced classification involves high stability against certain bacterial enzymes, making it particularly effective against many Gram-negative pathogens. For instance, it is frequently used to address bacterial middle ear infections and urinary tract issues.


Composition, Origin, and Available Forms

Cefine is a single-ingredient product driven by its sole active ingredient, Cefixime, which is identified as a semisynthetic compound. This means its structure is based on natural materials but has been chemically modified to enhance its therapeutic action and stability. Cefine is prepared for oral administration and is formulated for a wide target audience, including both adults and pediatric patients. This is reflected in its diverse dosage forms, which include the standard tablet, capsule, and a readily available liquid suspension and chewable tablet, simplifying its use for children.


General Purpose and Bactericidal Action

The fundamental general purpose of Cefine is the swift elimination of infections caused by susceptible bacteria. It achieves this through bactericidal action, a direct mechanism that actively kills the targeted bacterial cells, rather than merely halting their growth. As an extended-spectrum oral cephalosporin, Cefixime provides effective bactericidal action against susceptible organisms. This ability to directly eliminate the source of the infection provides a reliable therapeutic outcome.

Regulatory References

  1. Cefixime: MedlinePlus Drug Information

What side effects are possible with Cefine?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety information for Cefine (Cefixime), based strictly on government regulatory documents.


Adverse Reaction Scope

The most commonly reported adverse reactions documented in regulatory sources are classified as Gastrointestinal Disorders, including diarrhoea, which is a Common effect (occurring in at least 1 in 100 patients). Other effects classified as Uncommon include headache, nausea, vomiting, and abdominal pain.

Adverse reactions are also grouped into System-Organ Classes such as Nervous System Disorders, Hepatobiliary Disorders, and Skin and Subcutaneous Tissue Disorders, which include less frequent reactions like skin rash and urticaria.


Serious Adverse Reactions and Safety Constraints

The regulatory label documents the potential for rare but clinically significant events. These Serious Adverse Reactions include severe cutaneous adverse reactions (such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), systemic hypersensitivity reactions (anaphylaxis), and Clostridium difficile-Associated Diarrhea (CDAD), which may manifest during or after therapy.

Safety constraints noted in official prescribing information include a risk of cross-hypersensitivity in patients with a history of severe penicillin allergy. Caution is also required for patients with renal impairment, as neurological effects like encephalopathy have been associated with its use in this population. Additionally, concomitant use with anticoagulants may be associated with an increase in prothrombin time. The possibility of superinfection (overgrowth of non-susceptible organisms) is noted with prolonged use. This structured information dictates the official boundaries of the medicine's safety characteristics.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Cefine (Cefixime) based on the potential for severe neurological effects and mandated emergency actions.

Scope of Overdose Regulatory Documentation
Documented Manifestations Overexposure may lead to signs of encephalopathy, including convulsions/seizures, confusion, and impaired consciousness.
Affected Systems Central Nervous System (CNS).
Risk Factors The risk of CNS toxicity is increased when overdose occurs in patients with impaired renal function due to reduced drug clearance.
Antidote Status No specific antidote is known for Cefixime overdose.

When Immediate Medical Help Is Required

Regulatory guidance mandates that immediate medical attention is required in the event of an overdose. Emergency services (such as 911) must be contacted immediately if the individual is experiencing critical, life-threatening signs, including seizure, collapse, trouble breathing, or inability to be awakened (unconsciousness).

Official Overdose Statements

  • The mandated treatment approach is symptomatic and supportive.
  • Management procedures may involve discontinuation of the drug, gastric lavage, and the administration of anticonvulsant therapy if clinically indicated for seizures.

Connection to the overall overdose profile

The overall profile is defined by the requirement for rapid intervention for neurological symptoms. Since no specific countermeasure is documented in the labeling, the official protocol focuses on supportive care and observation until the acute manifestations subside.

Therapeutic Uses of Cefine

What Cefine Treats: Main Uses and Benefits

Cefine (Cefixime) is commonly used across several therapeutic domains where a susceptible bacterial infection drives symptoms related to inflammatory or irritative states, and is considered relevant for managing acute symptomatic episodes. The drug is relevant for easing symptomatic discomfort across several major therapeutic areas.


This medication is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant for conditions that present with systemic or localized discomfort, including acute otitis media (middle ear infection), pharyngitis and tonsillitis, uncomplicated urinary tract infections (UTIs), certain genitourinary infections, and acute exacerbations of chronic bronchitis. It helps address symptom clusters that may appear suddenly, including sore throat, fever, and localized pain.

It is commonly used to manage susceptible infections in pediatric patients and adults with penicillin allergies, providing supportive relief during difficult episodes.


Quick Fact: Support for Localized Discomfort Cefine is used for managing symptoms that create noticeable functional strain, such as painful urination (dysuria) in uncomplicated UTIs and ear pain associated with acute middle ear infections.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefine — Official Regulatory Information

The eligibility profile for Cefine (Cefixime) is defined by official governmental regulatory documents.

Contraindications and Non-Eligibility

Use of Cefine is strictly contraindicated in patients with a documented allergy to Cefixime or to any other cephalosporin-class antibiotic. Absolute caution is also required for patients with a history of severe penicillin allergy due to the potential risk of cross-hypersensitivity. The medicine must not be used in infants younger than six months of age, as safety and efficacy have not been established in this age group.

Conditional and Restricted Use

  • Adults and pediatric patients six months of age and older are generally eligible for use.
  • Renal Impairment: Use is conditional and requires caution in patients with impaired renal function due to the need for dosage adjustment.
  • Comorbidities: The medicine should be used with caution in individuals with a history of gastrointestinal disease, particularly colitis. The chewable tablet formulation is restricted for patients with Phenylketonuria (PKU) because it contains phenylalanine.
  • Pregnancy and Lactation: Cefine is generally not recommended during pregnancy and breastfeeding. It should only be used in pregnant women if clearly needed, and consideration should be given to temporarily discontinuing nursing during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cefine (Cefixime) by specifying effects on co-administered medicines and substances, and outlining patient-specific considerations.


Documented Drug-Drug Interactions

Interacting Substance Official Regulatory Outcome
Warfarin and Anticoagulants Co-administration has been reported to cause an increased prothrombin time (PT), which is associated with the cephalosporin class effect on prothrombin activity.
Carbamazepine Co-administration has been reported to result in elevated plasma concentrations of Carbamazepine.

Substance and Condition-Specific Notes

The regulatory information specifies that Cefine’s absorption kinetics are altered by food. When administered with food, the overall extent of absorption is not significantly changed, but the rate of absorption is slowed, resulting in an approximate 0.8-hour delay in reaching maximal plasma concentration. No major interaction with alcohol or specific herbal products is explicitly documented in the official labeling.

Official prescribing information notes that the prolongation in prothrombin time observed with anticoagulants may be of increased clinical significance in patients with documented renal or hepatic impairment, linking the interaction outcome to the patient’s underlying condition.

Mechanism of Action

Disrupting Bacterial Cell Wall Synthesis

Cefine's primary mechanism involves the irreversible inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial transpeptidases essential for forming the structural backbone of the cell wall . This targeted molecular action prevents the necessary cross-linking of the peptidoglycan polymer. The resulting weak and defective wall triggers the cell's own autolytic enzymes, which results in bacterial cell lysis due to internal osmotic pressure.


The Bactericidal Cascade

This action is categorized as bactericidal, meaning the mechanism directly results in the destruction of susceptible pathogens. By modifying the early molecular steps of cell wall assembly, Cefine initiates a cascade that results in the destruction of the pathogenic microbial population. This process is categorized as a peripheral action, focusing its activity directly on the invading bacterial cells.


Stability Against beta-Lactamase Enzymes

Cefine is designed with a chemical structure that exhibits enhanced stability against hydrolysis by many common bacterial defense mechanisms, specifically the deactivation carried out by beta-lactamase enzymes. This stability allows the drug to retain activity against some bacteria that utilize beta-lactamase enzymes, thereby permitting the continued inhibition of PBPs.

Dosage and Administration Information

How to Use Cefine

Cefine (Cefixime) is structured for oral administration only, available as tablets, capsules, chewable tablets, and an oral suspension. The medicine is used according to standardized dosing schedules that govern the amount taken and the duration of the course.


Administration Guidelines

Feature General Instruction Summary
Standard Adult Dosing 400 mg daily, which may be given as a single dose or divided into 200 mg every 12 hours.
Dosing Frequency Typically once daily or twice daily (every 12 hours).
Timing with Food May be administered without regard to food (can be taken with or without meals).
Course Duration The usual course of treatment is 7 to 14 days, with a minimum of 10 days required for infections caused by S. pyogenes.

Population and Form Adjustments

Specific adjustments are applied for vulnerable populations and proper handling of dosage forms. Pediatric patients (6 months and older) are typically dosed at 8 mg/kg of body weight per day, administered as a single dose or divided twice daily.

For patients with severely reduced kidney function (Creatinine Clearance <= 20 mL/min), the dose should generally not exceed 200 mg once daily.

Proper use of the forms involves that chewable tablets must be chewed or crushed before swallowing, and the oral suspension must be shaken well before each use. Tablets and capsules are not substituted for the oral suspension in certain pediatric settings due to differences in absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefine

This overview describes the scope and types of official research that have examined Cefine (Cefixime), focusing on the conditions studied and the kind of data collected, without offering clinical guidance or interpretation of individual outcomes. The evidence presented here is based on findings reported by regulatory bodies and peer-reviewed scientific literature.


Evidence for Use in Acute Otitis Media (AOM - Middle Ear Infection)

Research for Cefine in AOM has primarily involved short-term Randomized Controlled Trials (RCTs) conducted with pediatric patients (children six months and older). The research explored how symptoms change over time and monitored the outcome measurements related to the elimination of specific bacterial pathogens. Trials reported measurements of clinical resolution in Cefixime-treated groups that were observed in a similar range to those measured in comparator-treated groups. Data describing long-term outcomes are not fully established, and follow-up durations were limited in the pivotal trials.


Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs) and Other Infections

For uncomplicated UTIs, the evidence base was evaluated in randomized prospective trials and studies involving both adults and pediatric patients. Outcomes related to symptomatic discomfort were monitored, alongside checking for the presence of bacteria in urine samples. Studies reported measurements of clinical and bacteriological outcomes. Evidence describing the role in more complex conditions is limited, and results apply mainly to the populations studied.

For Pharyngitis/Tonsillitis and Acute Exacerbations of Chronic Bronchitis (AECB), clinical studies explored short-term symptom changes and pathogen eradication measurements. Regarding pharyngitis, regulatory documents note that data establishing its association with the long-term prevention of rheumatic fever are not available. The evidence highlights what is known—and what is still uncertain—about Cefine's research profile.

Key Studies & References

  1. Effectiveness and tolerance of cefixime in comparison with penicillin V in bacterial pharyngitis and tonsillitis in children. Cefixime Study Group
  2. Is cefixime (Cefixime) effective for treating urinary tract infections (UTIs)? - Dr.Oracle (Summarizing clinical efficacy evidence for uncomplicated UTIs)

Frequently Asked Questions (FAQ)

Common questions about Cefine (FAQ)


Q: How quickly should I expect Cefine to start working?

A: Based on patient information and clinical expectations, individuals often begin to feel an improvement in their symptoms during the first few days of treatment with Cefine. Completing the entire course of medication as prescribed is generally recommended to maximize the chance of a successful outcome.


Q: Is Cefine meant for short-term use, or can it be taken long-term?

A: Cefine is generally prescribed for short-term courses, often lasting 7 to 14 days, to treat specific bacterial infections. Official regulatory documents indicate that prolonged use may increase the risk of developing drug-resistant bacteria or superinfection (a new infection).


Q: Is it normal to feel tired or dizzy when first starting Cefine?

A: Official product information reports that side effects such as dizziness and drowsiness are potential adverse effects associated with this medication. If these effects are experienced and cause concern, individuals should consult with a healthcare professional.


Q: What should I watch for that might indicate a serious reaction to Cefine?

A: Individuals experiencing severe symptoms should seek immediate emergency medical attention. These include signs of a severe allergic reaction like trouble breathing or swelling of the face, tongue, or throat. Other serious signs include severe stomach pain accompanied by watery or bloody diarrhea, or yellowing of the skin or eyes (jaundice).


Q: Can Cefine cause skin rashes or sensitivity to the sun?

A: Skin rashes and severe skin reactions are listed in the official adverse reactions section for Cefine. However, typical regulatory documents do not generally list sensitivity to the sun (photosensitivity) as an established adverse effect.


Q: Does Cefine affect mental focus or sleep patterns?

A: Official adverse event information indicates that Cefine can cause side effects like headache, dizziness, drowsiness, anxiety, and confusion. These effects could potentially impact mental focus. Additionally, increased night-time urination has been noted.


Q: Is there a risk of developing long-term health issues from using Cefine?

A: Regulatory information notes the risk of developing Clostridium difficile-Associated Diarrhea (CDAD), which may occur up to two months after treatment ends. Additionally, prolonged use may increase the risk of developing drug-resistant bacteria.


Q: Are there any dietary restrictions when taking Cefine?

A: Generally, no major dietary restrictions are specified, and Cefine can be taken with or without food. The main restriction is that the chewable tablet formulation contains phenylalanine and must be avoided by patients with the metabolic disorder Phenylketonuria (PKU).


Q: Is Cefine processed by the liver or excreted by the kidneys?

A: Cefine, whose active ingredient is Cefixime, is primarily eliminated from the body by the kidneys (renal excretion). Some excretion of the drug also occurs through the bile. This is why official warnings mention the need for dose adjustments in patients with severely impaired kidney function.


Q: Why do doctors prescribe Cefine over other treatment options?

A: Official information indicates that Cefine is structurally designed with enhanced stability against certain bacterial defense mechanisms, such as beta-lactamase enzymes. This may allow the drug to be effective against some strains of bacteria that have developed resistance to other similar antibiotics.


Q: What are the guidelines for using Cefine if I have diabetes?

A: Official guidelines note that Cefine can interfere with certain types of urine glucose tests (such as Clinitest or Benedict's solution), potentially leading to false results. Patients with diabetes are often advised to use specific enzyme-based testing methods (like TesTape or Clinistix) to monitor their glucose while taking this medication.


Q: Is it possible to become resistant to Cefine over time?

A: Yes, regulatory documents indicate that using any antibacterial drug when it is not needed increases the risk of bacteria developing resistance. Cefine-resistant isolates of certain pathogens have been identified in clinical settings.


Q: Do I need to take Cefine at the same time every day?

A: It is recommended to take Cefine at around the same times every day, whether it is prescribed once or twice daily. This approach helps maintain a consistent level of the medication in the body, which is important for effectively treating the infection.


Q: How long does Cefine stay active in the body after a dose?

A: According to official pharmacokinetic data, the average elimination half-life for the active ingredient in Cefine is approximately 3 to 4 hours in adults. The half-life is the time it takes for half of the drug to be cleared from the bloodstream.


Q: What happens if I stop taking Cefine suddenly?

A: Official patient information indicates that stopping antibiotic treatment too soon or skipping doses may result in the infection not being completely cleared. This incomplete treatment can also increase the risk of the surviving bacteria becoming resistant to the antibiotic.


Q: Do the side effects of Cefine generally go away over time?

A: The most common side effects associated with Cefine often do not require specific medical attention and may resolve gradually as the body adjusts to the medication. If symptoms persist or worsen, consulting a healthcare provider is generally recommended.


Q: Does Cefine cause changes in appetite or weight?

A: Official regulatory documents list loss of appetite as a potential adverse effect of Cefine. Changes in overall body weight are not typically listed as a common side effect of the medication.


Q: Can I take Cefine with common over-the-counter pain relievers like ibuprofen?

A: Interactions with common non-prescription pain relievers like ibuprofen are not explicitly listed in regulatory documents. However, caution is generally advised with nonsteroidal anti-inflammatory drugs (NSAIDs) because Cefine may potentially affect blood coagulation factors.


Q: What is the risk of interaction if I am taking blood pressure medication?

A: Cefine is generally not reported to interact significantly with the core classes of blood pressure medications. It is generally recommended that patients inform their healthcare provider of all concurrent treatments before starting any new medication.


Q: Is Cefine appropriate for older adults?

A: Cefine is generally considered appropriate for older adults using the standard adult dose. However, official information highlights that caution and dose adjustment are required if the older adult has any form of impaired kidney function.


Q: Can people with a history of heart problems use Cefine?

A: There is no specific contraindication (reason to avoid) for Cefine based solely on a history of heart problems. Patients with heart conditions may use it, but dose adjustment may be necessary if they have concurrent severe kidney impairment.


Q: Does Cefine require any special blood tests or monitoring?

A: Monitoring of prothrombin time (PT), a measure of blood clotting, may be necessary for patients with certain risk factors, such as those taking anticoagulants or those with kidney or liver impairment. The drug may also interfere with certain lab tests.


Q: Is there a generic version of Cefine available on the market?

A: The active ingredient in Cefine, Cefixime, is widely available as a generic product from multiple manufacturers. Regulatory information often refers to the drug by this generic name.


Q: Can Cefine be taken with acid reflux medication?

A: Drug interaction studies suggest that taking Cefine with certain acid reflux medications, specifically H2 blockers, may reduce the availability of the acid reflux drug. Antacids are typically recommended to be taken separately to prevent potential interference with Cefine’s effectiveness.


Q: What is the recommended protocol if a dose of Cefine is missed?

A: The protocol for a missed dose typically recommends taking it as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose is usually skipped. Official patient information advises against taking a double dose.


Q: Are there different strengths of Cefine available?

A: Yes, regulatory information confirms that the active ingredient, Cefixime, is available in multiple forms and strengths. This includes solid forms (like 400 mg capsules) and oral suspensions (such as 100 mg/5 mL and 200 mg/5 mL) to accommodate various dosing needs.


Q: Are there any warnings about operating machinery while using Cefine?

A: Yes, official safety warnings advise caution regarding driving or operating heavy machinery. This warning is based on the potential for Cefine to cause side effects such as dizziness or drowsiness, which could impair coordination and judgment.

How should Cefine be stored and disposed of?

How to Store and Dispose of Cefine?

Storage and disposal requirements for Cefine (Cefixime) are strictly defined by regulatory labeling to maintain product stability and ensure public safety.


Official Storage Conditions

Dosage Form Required Storage Temperature In-Use Stability Limit
Tablet/Capsule (Solid) Store at mathbf20^circC to mathbf25^circC (mathbf68^circF to mathbf77^circF). None beyond expiration date.
Reconstituted Suspension Store at mathbf20^circC to mathbf25^circC (Do not refrigerate certain formulations). Must be discarded 14 days after mixing.

The medicine must be kept out of the sight and reach of children. The powder for oral suspension must be stored in a tightly closed container and protected from light.


Disposal Requirements

Expired or unused Cefine should be disposed of through an authorized drug take-back program. If this option is unavailable, the medication must be mixed with an undesirable substance and sealed before being placed in the household trash. Do not flush Cefine down a sink or toilet unless explicitly instructed by official drug labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefine found in:

A-Z Index: